Certara, Inc.: directors' dealings · United States · SEC (Form 4)

About Certara, Inc.

Certara, Inc. is a United States life-sciences company listed on the US market, NASDAQ: CERT, and focused on serving pharmaceutical, biotechnology, and regulatory stakeholders. Headquartered in Radnor, Pennsylvania, United States, Certara is built around model-informed drug development (MIDD): the use of simulation, quantitative modeling, and advanced analytics to improve decision-making across the drug-development lifecycle. In practical terms, the company sits at the intersection of scientific software, regulatory science, and drug-development services, making it a specialized, high-value niche provider rather than a broad-based healthcare vendor. ([certara.com](https://www.certara.com/announcement/certara-announces-new-corporate-headquarters/?utm_source=openai)) The company’s origins date back to 2008, when Certara was formed from a combination of modeling and biosimulation assets and expertise. Since then, it has expanded through a series of targeted acquisitions and product development initiatives that broadened its software stack and service capabilities. Over time, Certara has built an international footprint spanning North America, Europe, and Asia-Pacific, which supports its work with global pharmaceutical clients and regulators. In April 2024, Certara announced the relocation of its corporate headquarters from Princeton to Radnor, reinforcing its operational base in the greater Philadelphia life-sciences corridor. ([certara.com](https://www.certara.com/our-story/?utm_source=openai)) Operationally, Certara is organized around two core pillars: software and services. On the software side, the company offers biosimulation tools, pharmacometrics platforms, PBPK and QSP capabilities, scientific data-management solutions, and cloud-based tools designed to unify end-to-end scientific workflows. On the services side, Certara supports clinical pharmacology, regulatory science, regulatory and medical writing, real-world evidence, market access, and early-development consulting. This integrated model is one of its key differentiators because it allows customers to move from discovery through clinical development and regulatory submission within a more cohesive framework. ([certara.com](https://www.certara.com/solutions/midd/?utm_source=openai)) From a competitive standpoint, Certara is widely viewed as a leading MIDD specialist with strong scientific credibility and a well-established customer base across large pharma and biotech. Its competitive edge comes from proprietary modeling capabilities, the combination of software and consulting, and deep regulatory know-how. The company’s global operating presence also matters, because its customers typically run multinational development programs that require localized expertise and regulatory coordination. ([certara.com](https://www.certara.com/solutions/midd/?utm_source=openai)) Recent corporate developments show a clear strategic focus. In October 2025, Certara launched Certara IQ, an AI-enabled QSP solution designed to strengthen biosimulation-driven drug development. In July 2025, it expanded its clinical technology collaboration with Merck, underscoring the company’s ability to deepen relationships with major pharmaceutical partners. More recently, in April 2026, Certara announced a definitive agreement to sell its Regulatory and Medical Writing business to Veristat, a move intended to sharpen its focus on integrated MIDD and clinical intelligence while concentrating investment on higher-priority platform areas. These actions suggest a company actively refining its portfolio toward more scalable, differentiated offerings. ([certara.com](https://www.certara.com/pressrelease/certara-expands-biosimulation-market-with-ai-driven-qsp-platform/?utm_source=openai))